Cytiva, a global life sciences company and part of Danaher, has expanded its Fast Trak process development and validation services facility in Bengaluru, India, strengthening support for biopharmaceutical companies in the region.
The enlarged centre, inaugurated on February 25, brings nearly 30,000 square feet of integrated capability for upstream and downstream process development, optimisation, scale-up and validation under one roof.
The expanded facility is designed to help biopharma developers shorten development timelines, reduce manufacturing risk and accelerate their journeys from early development to commercialization. Alongside technical services, it offers immersive training programmes aimed at equipping scientists and engineers with the skills needed for modern bioprocessing.
By consolidating core process development functions in Bengaluru, Cytiva aims to provide comprehensive infrastructure and expertise that supports a wide range of modalities, including monoclonal antibodies, recombinant proteins, plasmid DNA, mRNA and viral vectors. The facility is compliant with biosafety and validation standards, offering services that help companies improve product quality, increase yield and meet regulatory requirements.
The expansion reflects broader momentum in India’s biopharma ecosystem, where increasing demand for biologics and biosimilars has driven investment in local development and manufacturing capabilities. Cytiva’s enhanced Fast Trak centre is positioned to offer domestic and Asia-Pacific customers greater access to global-standard process development support as the industry continues to grow.
